Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Stargardt Disease Clinical Trials

12 recruiting trials for Stargardt Disease. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
12
Total Trials
12
Recruiting Now
0
Phase 3 Trials
9
Sponsors

Recruiting Trials

RECRUITINGNCT02435940

Inherited Retinal Degenerative Disease Registry

The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by...

Sponsor: Foundation Fighting BlindnessEnrolling: 200001 location
RECRUITINGNCT07425574

A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults

Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye. In...

Sponsor: Astellas Pharma Global Development, Inc.Enrolling: 901 location
RECRUITINGPhase 1 / Phase 2NCT07439887

Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients...

A Phase 1/2, open-label, non-randomized, dose-escalation study, where a minimum of 9 and a maximum of 18 eligible patients with Stargardt Disease will be enrolled sequentially in...

Sponsor: Ray Therapeutics, Inc.Enrolling: 182 locations
RECRUITINGNCT06435000

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic...

This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene This is a...

Sponsor: Splice BioEnrolling: 7520 locations
RECRUITINGPhase 1 / Phase 2NCT06942572

A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary...

This Phase 1/2 study will evaluate the safety, tolerability, and preliminary efficacy of subretinal SB-007 administration to determine dose selection in subjects with Stargardt's...

Sponsor: Splice BioEnrolling: 575 locations
RECRUITINGNCT03011541

Stem Cell Ophthalmology Treatment Study II

This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.

Sponsor: MD Stem CellsEnrolling: 5004 locations
RECRUITINGPhase 2 / Phase 3NCT05956626

A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease

Phase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study, that will enroll fifty-one (51) subjects. Subjects will be enrolled in a...

Sponsor: OcugenEnrolling: 5114 locations
RECRUITINGNCT06805474

A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT

The goal of this observational study is to assess the reliability and validity of the 9-object MLSDT for evaluation of participants with moderate to severe vision impairment when...

Sponsor: Nanoscope Therapeutics Inc.Enrolling: 301 location
RECRUITINGPhase 1NCT06319872

The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration

Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and...

Sponsor: University of RochesterEnrolling: 151 location
RECRUITINGNCT06375239

Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal...

The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The...

Sponsor: Ray Therapeutics, Inc.Enrolling: 1201 location
RECRUITINGNCT07502664

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited...

The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The...

Sponsor: Ray Therapeutics, Inc.Enrolling: 251 location
RECRUITINGNCT07266584

Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration

The objective of this study is to evaluate the efficacy and safety of the PRIMA Products in participants with inherited retinal degeneration affecting the macula (including but...

Sponsor: Science CorporationEnrolling: 51 location